Issue of predicting the risk of thromboembolic complications in patients with lymphoproliferative diseases

The incidence of malignant lymphomas has been increasing in recent years worldwide. These diseases are often accompanied by venous thromboembolic complications (VTEC). development VTEC leads to interrupting therapy, mortality and significant rising treatment costs. Anticoagulants effective prophylaxis. Prescribing anticoagulant therapy is based on different risk scales, which far from perfect. search additional features for hemostasis assessment can increase the prognostic value these scales. optimization scales improve efficacy decrease an thrombotic events patient with lymphomas. article presents a literature review own clinical observations regarding patients lymphoproliferative diseases.